CRIS News & Events

Curis announced that eleven clinical sites have been initiated and are now open for patient enrollment in its Phase 2 TakeAim CLL study evaluating emavusertib in combination with zanubrutinib in patients with Chronic Lymphocytic Leukemia. The company also reaffirmed its guidance for the dosing of the initial five patients in the TakeAim CLL study by the end of July, with data expected in December 2026. In addition, the company reported that its stockholders approved a reverse stock split proposal at the special meeting of stockholders held on June 25. Stockholders approved a proposal to effect a reverse stock split of its issued and outstanding shares of common stock at a ratio ranging from 1-for-5 to 1-for-25, in furtherance of the company's regaining compliance with Nasdaq's $1.00 bid price rule, said Curis, which adds that the company intends to announce the specific ratio and effective date in advance of the reverse stock split becoming effective.

Reports Q1 revenue $0, consensus $1.86M. As of March 31 Curis's cash and cash equivalents totaled $15.0M, and the Company had approximately 40.0 million shares of common stock outstanding.

Curis believes its cash and cash equivalents as of March 31 of $15.0M, together with anticipated gross proceeds of up to an additional $20.2M from the exercise of the January 2026 PIPE Financing Series B Warrants upon the public announcement of dosing the 5th CLL patient in our TakeAim CLL study expected later this year, should enable the Company's planned operations into the second half of 2027.

Reports Q4 revenue $1.14M, consensus $3.25M. Curis believes its cash and cash equivalents as of December 31, 2025, together with initial and expected gross proceeds of the January 2026 PIPE Financing Series B Warrants, should enable the company's planned operations into the second half of 2027.